Synthesis and Biological Evaluation of Novel Anthranilamide Derivatives as Anticancer Agents
News Oct 23, 2013
A new series of anthranilamide derivatives were synthesized and evaluated for their antiproliferative activities against human colon carcinoma cell lines (HCT 116) and human breast adenocarcinoma cell lines (MDA-MB-231) in vitro. The bioassay results indicated that compounds 7a-7d, 11a, and 11b with flexible linkers showed promising antiproliferative activity against both cell lines. Among the compounds synthesized, 7c showed the most significant antiproliferative activity. Flow cytometric analysis indicated that 7c inhibited HCT 116 and MDA-MB-231 cell growth by inducing apoptosis in a dose-dependent manner and suppressed HCT 116 cell proliferation by G1 and S phase arrest. Compound 7c may serve as a lead candidate in the development of novel anticancer agents.
This article was published online in Drug Discoveries and Therapeutics and is free to access.
Lab Innovations 2018 – Registration Opens and Keynotes AnnouncedNews
Learn and earn CPD points at the UK’s only lab-dedicated showcase and scientific seminar series.READ MORE
Synthesis Strategy Could Mean Wave of New Medicinal CompoundsNews
In pharmacology, not all molecular structures are created equal. Some frameworks are overrepresented in nature, making them especially attractive to scientists on the hunt for more effective drugs. One such structure, the carbocyclic 5-8-5 fused ring system, is notoriously difficult to produce using conventional laboratory methods. Now, an innovative synthetic technique could unlock these elusive structures.READ MORE